We also intend to expand our directed program of investigator-sponsored trials in 2013 to other
hematologic myeloid malignancies, including myelodysplastic syndromes and acute myelogenous leukemia.
The company better act fast before competition comes up with alternatives earlier than that!! Otherwise, Huh and Scarlett just can't sit on the million-dollars seats they occupy!!